ART Options and Treatment Decisions for Women of Reproductive Potential


Monica Gandhi, MD, MPH
University of California San Francisco


March 26, 2019 - 10:00 AM


March 26, 2019 - 11:15 AM


Assessment of Needs

The webinar will go over the current options for antiretroviral regimens in women of reproductive potential and during pregnancy, with particular attention to pharmacokinetic changes and safety. Further, the presentation will go over recent data on neural tube defects with dolutegravir use in early pregnancy and the resultant changes in WHO guidelines for ART during pregnancy. Finally, the presentation will explore ways in which ART should be further studied in women throughout their lifespan, including during pregnancy and reproductive years.

Learning Objectives

On completion of this webinar, learners will be able to:

  • Describe the recent guidelines for ART options in women of reproductive potential and pregnant women
  • Identify the neural tube defects and other fetal concerns with ART agents
  • Understand ways in which the pharmacokinetics and safety profile of ART agents during pregnancy can be explored


Who Should Attend

This advanced webinar is designed for clinical decision makers who are actively involved in HIV care and research.

This activity is also relevant for registered nurses, PharmDs, and other health professionals.

Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.

Registration closes on Monday, March 25, 2019, 4:00 PM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at registration“at” or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credits

This activity is eligible for ANCC credit; see the final CNE activity announcement for details.

Pharmacy Credits

Accreditation Council for Pharmacy Education logo This activity is eligible for ACPE credit; see the final CPE activity announcement for details.

Grant Support

Requests for educational grants have been made to commercial companies with competing products. Information on grant support will be posted on the IAS–USA website as it becomes available.

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration“at” or 415-544-9400.